Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2011-09-21 Earnings Release
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo announces positive results supporting OX219 for treatment of opioid dependence
Earnings Release Classification · 1% confidence The document is explicitly titled "Press release" and announces positive clinical study results for a drug candidate (OX219), including strategic decisions regarding regulatory pathways (FDA 505(b)(2)) and financial implications (asset write-off). This content structure—a brief announcement of key operational/clinical progress, often released before a full financial report—is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on clinical milestones and strategic direction rather than comprehensive quarterly financials (which would suggest IR or 10-K), and it is a direct announcement of results, ER is the most appropriate fit. It is not a transcript (CT), a formal annual report (10-K), or a presentation (IP). Q3 2011
2011-09-21 English
Orexo meddelar positiva resultat för OX219 för behandling av opioidberoende
Legal Proceedings Report Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces positive clinical trial results for a drug candidate (OX219) and outlines the regulatory pathway (505(b)(2) routine with the FDA). It discusses financial implications (asset write-off) and market size projections. This content is characteristic of an initial announcement of key financial/operational news, rather than a comprehensive report (10-K, IR) or a transcript (CT). It fits the definition of an Earnings Release (ER) as it announces key operational and financial highlights, even though it's not strictly quarterly earnings, but a major development announcement often grouped with ERs or similar immediate disclosures. Given the options, 'ER' (Earnings Release) is the closest fit for a major, time-sensitive operational/financial update announcement, although 'RNS' (Regulatory Filings) is also plausible as a general announcement. Since it focuses on a major positive development and its financial impact, ER is selected over the generic RNS.
2011-09-21 Swedish
Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as Chief Commercial Officer
Board/Management Information Classification · 1% confidence The document is explicitly titled as a "Press release" dated September 16, 2011. The core content announces the appointment of Nikolaj Sørensen as Chief Commercial Officer, detailing his background and responsibilities. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The document length is relatively short (3512 chars), but its content is a direct announcement, not a notification about another report's publication (RPA/RNS).
2011-09-16 English
Orexo stärker den kommersiella kompetensen och utser Nikolaj Sørensen till Chief Commercial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated September 16, 2011, announcing the appointment of Nikolaj Sørensen as the new Chief Commercial Officer (CCO) and detailing his extensive background in the pharmaceutical industry (Pfizer, BCG). This announcement concerns a change in senior management personnel. According to the definitions, the category for 'Announcement of changes in the company's board of directors or senior management' is Board/Management Information (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2011-09-16 Swedish
Orexo utser Carl-Johan Blomberg till ny CFO
Board/Management Information Classification · 1% confidence The document is a press release dated August 31, 2011, announcing the appointment of Carl-Johan Blomberg as the new CFO of Orexo AB, effective September 1st. This announcement details a change in senior management personnel. According to the definitions, the category for 'Announcement of changes in the company's board of directors or senior management' is Board/Management Information (MANG). The document length is short (1946 chars), but its content is a direct announcement of a management change, not an announcement about the publication of a separate report.
2011-08-31 Swedish
Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing a specific management change: the appointment of a new Chief Financial Officer (CFO), Carl-Johan Blomberg. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2011-08-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.